umanigen (OTCQB:HGEN) and Lonza announce a strategic collaboration to expand the manufacturing capacity for lenzilumab for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.
The collaboration enables Humanigen to leverage Lonza’s monoclonal antibody manufacturing and regulatory expertise.
This partnership will provide additional capacity for cGMP production of lenzilumab with operations intended to start in 2021 at Lonza’s manufacturing facilities at Hayward, USA.
Technology transfer is expected to begin in Q3.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.